United Therapeutics Corporation

UTHRleader

United Therapeutics focuses on life-saving treatments for pulmonary arterial hypertension and is pioneering xenotransplantation — using genetically modified pig organs for human transplant. It has over $5B in cash and no long-term debt.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($2.8B)

靜態數據（加載即時財務…）

Tyvaso Products (55%)

Remodulin (25%)

Orenitram (12%)

Other (8%)

業務部門構成與主要客戶

產品詳情

Tyvaso / Tyvaso DPI (Inhaled Treprostinil)55%

Pulmonary arterial hypertension (PAH) + pulmonary hypertension associated with ILD. Fastest-growing drug.

Remodulin (Treprostinil Infusion)25%

Continuous subcutaneous/IV infusion for severe PAH.

Orenitram (Oral Treprostinil)10%

Oral extended-release treprostinil for PAH.

Unituxin / Transplant Pipeline10%

Pediatric neuroblastoma + regenerative medicine (xenotransplantation organs).

供應鏈關係

宏觀與市場背景

헬스케어行業新聞

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化劑

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

點擊「取得 AI 分析」以獲得 United Therapeutics Corporation 的 AI 供應鏈分析。

企業資訊

總部

Silver Spring, MD

成立時間

1996

員工人數

2,600

官網

unither.com

行業概況 — 헬스케어

行業新聞